Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 10,851 matching trials from the live ClinicalTrials.gov search.
Filters: Columbus, Ohio Clear all
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

NCT01059630
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Obinutuzumab, Bendamustine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
33
States / cities
Mobile, Alabama • Casa Grande, Arizona • Rogers, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Nov 5, 2026, 5:13 AM EST
Recruiting Phase 3 Interventional

Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

NCT06372964
View directory record Official record
Conditions
Bipolar Depression
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
56
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 5, 2026, 5:13 AM EST
Completed Not applicable Interventional Results available

Adaptive Cardiac Resynchronization Therapy Study

NCT00980057
View directory record Official record
Conditions
Heart Failure
Interventions
Adaptive CRT (aCRT), Echo
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
55
States / cities
Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Nov 5, 2026, 5:13 AM EST
Completed Phase 2 Interventional

External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer

NCT00006365
View directory record Official record
Conditions
Prostate Cancer
Interventions
brachytherapy, iodine I 125, radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
236
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Nov 5, 2026, 5:13 AM EST
Completed Phase 1 Interventional

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

NCT05241834
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
Interventions
LOXO-260
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 5, 2026, 5:13 AM EST
Recruiting Phase 2 Interventional

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

NCT04317534
View directory record Official record
Conditions
NSCLC, Stage I
Interventions
Pembrolizumab
Drug
Lead sponsor
Greg Durm, MD
Other
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
13
States / cities
Tampa, Florida • Chicago, Illinois • Indianapolis, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Nov 5, 2026, 5:13 AM EST
Terminated Phase 2 Interventional Results available

A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

NCT03547999
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
mFOLFOX6, MVA-BN-CV301, FPV-CV301, Nivolumab
Drug · Biological
Lead sponsor
Patrick Boland
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Duarte, California • Miami, Florida • Westwood, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Nov 5, 2026, 5:13 AM EST
Completed Phase 3 Interventional Results available

Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants

NCT04492020
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant 100 mg, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
73
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Nov 5, 2026, 5:13 AM EST
Completed Phase 3 Interventional Results available

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

NCT02526160
View directory record Official record
Conditions
X-linked Hypophosphatemia
Interventions
burosumab, Placebo
Biological · Other
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Nov 5, 2026, 5:13 AM EST
Terminated Phase 3 Interventional Results available

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

NCT02516423
View directory record Official record
Conditions
Solitary Osseous Plasmacytoma
Interventions
ixazomib, lenalidomide, dexamethasone, zoledronic acid
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
388
States / cities
Anchorage, Alaska • Burbank, California • Clovis, California + 267 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 5, 2026, 5:13 AM EST
Completed Not applicable Interventional Results available

PRP vs PRP Plus IGF for Patellar Tendinosis

NCT04350827
View directory record Official record
Conditions
Tendinopathy, Patellar Ligament, Platelet-Rich Plasma
Interventions
Platelet Rich Plasma, Platelet Rich Plasma plus IGF
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Nov 5, 2026, 5:13 AM EST
Completed Phase 1 Interventional

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

NCT02830542
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
SER-262, Placebo
Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Athens, Alabama • Fountain Valley, California • La Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Nov 5, 2026, 5:13 AM EST
Completed Phase 2 Interventional

A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer

NCT00088270
View directory record Official record
Conditions
Locally Advanced or Metastatic Adenoca of the Biliary Tract
Interventions
OSI-7904L, 5-Fluorouracil/Leucovorin
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
6
States / cities
Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2006 · Synced Nov 5, 2026, 5:13 AM EST
Completed Phase 3 Interventional Results available

A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease

NCT02394028
View directory record Official record
Conditions
Crohn Disease
Interventions
Etrolizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
62
States / cities
Arcadia, California • La Jolla, California • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Nov 5, 2026, 5:13 AM EST
Terminated No phase listed Observational

A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

NCT04655911
View directory record Official record
Conditions
Mucopolysaccharidosis III-B
Interventions
ABO-101
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Nov 5, 2026, 5:13 AM EST
Completed Phase 1 Interventional

A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis

NCT03257644
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib phosphate cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Hoover, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Nov 5, 2026, 5:13 AM EST
Completed Phase 3 Interventional

Nutrition Intervention in Treating Women With Breast Cancer

NCT00002564
View directory record Official record
Conditions
Breast Cancer
Interventions
educational intervention, therapeutic dietary intervention
Other · Procedure
Lead sponsor
Institute for Cancer Prevention (IFCP)
Other
Eligibility
48 Years to 78 Years · Female only
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Nov 5, 2026, 5:13 AM EST
Completed No phase listed Observational

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

NCT00772200
View directory record Official record
Conditions
Childhood Malignant Neoplasm
Interventions
Cognitive Assessment, Quality-of-Life Assessment
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Month and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
163
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 5, 2026, 5:13 AM EST
Active, not recruiting Not applicable Interventional

A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction or Revision Reconstruction

NCT02724371
View directory record Official record
Conditions
Breast Reconstruction, Revision Breast Reconstruction
Interventions
Mentor Larger Size MemoryGel Ultra High Profile Breast Implant
Device
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
30
States / cities
Montgomery, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 5, 2026, 5:13 AM EST
Completed Phase 2 Interventional Results available

Ponatinib in Advanced NSCLC w/ RET Translocations

NCT01813734
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Ponatinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Orange, California • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Nov 5, 2026, 5:13 AM EST
Not listed Not applicable Interventional

REDUCE LAP-HF RANDOMIZED TRIAL I

NCT02600234
View directory record Official record
Conditions
Heart Failure
Interventions
Inter-Atrial Shunt Device, Intracardiac Echo
Device · Other
Lead sponsor
Corvia Medical
Industry
Eligibility
40 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
17
States / cities
Tucson, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Nov 5, 2026, 5:13 AM EST
Completed Phase 2 Interventional Results available

Radiation Therapy in Treating Young Patients With Gliomas

NCT00238264
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
radiation therapy
Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 20 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
127
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 109 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Nov 5, 2026, 5:13 AM EST
Completed Phase 2 Interventional

Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00023699
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
gefitinib
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
50
States / cities
Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Nov 5, 2026, 5:13 AM EST
Completed Phase 2 Interventional

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

NCT03616834
View directory record Official record
Conditions
Solid Tumors
Interventions
Tomivosertib (eFT-508)
Drug
Lead sponsor
Effector Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Nov 5, 2026, 5:13 AM EST